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Objective: Microfibrillar-associated protein 5 (MFAP5) is an extracellular matrix (ECM) glycoprotein, which is colocalized with
microfibrils in elastin networks. Its function in adipose tissue (AT) is not known. We have recently shown that the expression of
MFAP5 is downregulated in AT along with weight reduction (WR) in persons with metabolic syndrome (MetS). The aim of this
work was to study whether the change of MFAP5 mRNA expression in response to WR is associated with markers of adiposity,
glucose metabolism and insulin resistance in human AT.
Design: Weight reduction intervention study in parallel study design (The Genobin study). Altogether 46 obese subjects with
impaired glucose tolerance and features of MetS were randomized to a WR (n¼28) or a control group (n¼18) lasting for
33 weeks.
Measurements: Circulating glucose and insulin concentrations were measured and subcutaneous AT biopsies were performed
before and after the intervention. The mRNA expression was studied by quantitative real-time PCR (QPCR).
Results: QPCR of human AT biopsy samples confirmed that MFAP5 is highly expressed in AT and its expression is decreased
during WR. The mRNA expression of MFAP5 correlated positively with body mass index, and the change in MFAP5 mRNA
expression during WR correlated positively with the change of body fat mass. Furthermore, the MFAP5 mRNA expression
correlated negatively with circulating fasting concentrations of adiponectin and interleukin (IL)-1b and positively with leptin,
insulin and IL-1Ra levels. In addition, the MFAP5 mRNA expression correlated positively with the mRNA expressions of
peroxisome proliferator-activated receptor gamma, cyclin D2 and A disintegrin and metalloproteinase domain 12, genes
involved in AT remodeling.
Conclusion: This study demonstrates that MFAP5 is highly expressed in human AT and is correlated with markers of insulin
resistance. Furthermore, it is possible that MFAP5 is related to ECM remodeling during development of obesity.
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Introduction
Obesity is a chronic low-grade inflammatory state, which is
characterized by an increase in circulating inflammatory
factors partly due to changes in cytokine and adipokine
production in adipose tissue (AT).
1 In addition to mature
adipocytes, AT is composed of different cell types in the
stromavascular fraction
1 that may have different roles in
obesity-related inflammation of AT. It has been suggested
that a proinflammatory state with a concomitant upregula-
tion of inflammation-related genes might lead to changes in
the expression of genes linked to the extracellular matrix
(ECM) in order to accommodate the growing AT.
2 Weight
reduction (WR) is an effective way to reverse the state of
inflammation and decrease biological markers of inflamma-
tion in the circulation, and also the expression of inflam-
matory markers in AT.
3
Genome-wide transcriptomics analysis performed from AT
of the subjects with metabolic syndrome (MetS) participating
in the Genobin study
4 showed that the ECM-associated
gene, microfibrillar-associated protein 5 (MFAP5),
5 also known
as MAGP2, was one of the genes, whose expression was
downregulated in subcutaneous AT along with WR and
improved insulin sensitivity. It was found that MFAP5 mRNA Received 4 April 2011; revised 10 June 2011; accepted 24 June 2011
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AT is not known. In this work, our aim was to investigate
whether the change of MFAP5 gene expression, along with
WR, is correlated with the measures of glucose metabolism
and body adiposity in the Genobin study individuals and
with circulating adipokines and expression of genes, which
were changed after WR.
Materials and methods
Altogether 75 overweight/obese (body mass index (BMI)
28–40kgm
 2) subjects aged 40–70 years were recruited
into the Genobin study (NTC00621205) described in detail
earlier.
4 The subjects had impaired fasting glucose or
impaired glucose tolerance, and at least two other features
of the MetS.
6 Subjects were randomly assigned to one of the
following groups: WR (n¼28), aerobic exercise training
(n¼15), resistance exercise training (n¼14) or control group
(n¼18),
4 but in this study only the data from the WR and
control groups were included and analyzed. The number of
study participants varied among the correlation analyses due
to missing values of the variables in some of the participants.
In addition, mRNA samples were not available from all the
participants. The final number of participants included in
the data analysis is indicated in the table footnote. Subjects
were matched for age, gender, BMI and the status of glucose
metabolism. Briefly, the WR group had an intensive WR
period lasting for 12 weeks during which the study subjects
followed detailed instructions given by a clinical nutritionist.
These instructions were based on a 4-day dietary record and
an interview. Between weeks 12 and 33, the aim was to
maintain the achieved reduction in weight. The control
group was asked not to change their lifestyle habits. The
intervention was performed in accordance with the stan-
dards of the Declaration of Helsinki. The Ethics Committee
of the district hospital region of Northern Savo and Kuopio
University Hospital approved the study plan. All participants
gave a written informed consent.
Glucose metabolism was measured using an oral glucose
tolerance test and by frequently sampled intravenous
glucose tolerance test, according to the Minimal Model
method,
7 at baseline and at the end of the intervention.
4
Insulin sensitivity index, glucose effectiveness and acute
phase insulin response to glucose were calculated by the
MINMOD Millenium software.
8
After an overnight fast, AT samples were taken by needle
biopsy from subcutaneous abdominal AT, before and after
the intervention under local anesthesia (10mgml
 1 lido-
caine) to collect 0.5–5g of AT for the mRNA expression
studies. AT samples were washed twice with phosphate-
buffered saline and treated with RNAlater according to
the instructions provided by the manufacturer (Ambion,
Austin, TX, USA), and stored in  801C, until used for RNA
extraction. RNA extraction, cDNA synthesis and quantitative
real-time PCR (QPCR) were performed as previously described
in detail.
4 Briefly, TRIzol method followed by purification
with RNeasy Mini Kit (Invitrogen, Carlsbad, CA, USA and
Qiagen, Valencia, CA, USA) were used for extracting total
RNA according to the manufacturer’s instructions. Nanodrop
(NanoDrop Technologies, Wilmington, DE, USA) was used
for measuring the RNA concentration and the A260/A280
ratio. RNA was reverse-transcribed into cDNA using
High-capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA) according to the instruc-
tions provided by the manufacturer. QPCR with TaqMan
chemistry (Applied Biosystems) by using ABI Prism 7500
analyzer (Applied Biosystems) was used for the confirmation
of microarray gene expression results. The analysis for the
relative quantity of a specific gene, before and after the
intervention in AT, was performed as described previously.
4
Expression of target genes were normalized to cyclophilin A1
(PPIA) expression.
The clinical data were analyzed using the SPSS software
for Windows version 14.0 (SPSS Inc., Chicago, IL, USA).
Data are given as mean±s.d., unless otherwise indicated.
The normality of distributions of the variables was tested
with the Kolmogorov–Smirnov test, with Lilliefors signifi-
cance correction. Logarithmic transformation was used to
achieve normal distribution, whenever needed (indicated in
tables and/or figures). General linear model for univariate
analysis was used to test the difference in fold-change values
of mRNA expression between the groups. Paired samples
t-test was used for comparing the baseline and endpoint
measurements within the study group. Correlation analyses
were carried out using Pearson’s method. Partial correlation
analysis with adjustment for weight at baseline and gender
was used when appropriate. The WR and control groups were
combined in the correlation analysis at baseline and when
studying the correlations of change values. At baseline,
this was carried out because the participants who were
randomized either to an intervention or a control group
represents the same risk population, all having MetS. Thus,
the participants were homogenous regarding the selection
criteria. After the intervention, the two treatment groups
were analyzed separately because of potential treatment
effect. Moreover, the correlations between the change of
MFAP5 mRNA expression and the changes of clinical
and biochemical measures were studied when the WR and
control groups were combined, but also separately, for both
the groups. For the clinical and biochemical measurements,
Po0.05 was considered as statistically significant.
Results
Values for body weight, fasting plasma glucose and serum
insulin concentration were at baseline 92.1±14.9kg,
6.2±0.4mmoll
 1 and 11.5±5.4pmoll
 1, and at the end of
the intervention 88.7±14.0kg, 5.9±0.3mmoll
 1 and 10.7±
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 1 for the WR group, respectively. The respective
values for the control group were 87.3±8.3kg, 6.4±
0.6mmoll
 1 and 9.9±5.0pmoll
 1 at baseline and 87.7±
9.0kg, 6.1±0.6mmoll
 1 and 10.6±6.0pmoll
 1 at the end
of the intervention, respectively.
The QPCR analysis for MFAP5 expression confirmed the
data obtained by microarray (Figure 1). When the compari-
sons were made within the groups, the mRNA expression
levels of MFAP5 showed significant decrease (94.2±49.0 to
81.7±41.7AU, P¼0.017) in the WR group and no change
was seen in the control group (106.4±40.4 to 109.4±
34.5AU, P¼0.636). Similar results were also obtained by
microarray showing that MFAP5 expression was significantly
downregulated in the WR group (P¼0.004).
4 Fold-change
results by QPCR showed a significant reduction in MFAP5
mRNA expression in the WR group (P¼0.028) when
compared with the control group.
Correlation analyses were performed with the combined
study groups at baseline. MFAP5 mRNA expression correlated
significantly at baseline with BMI (Table 1). Moreover, the
expression of MFAP5 correlated significantly with fasting
serum insulin concentration at baseline, when adjusted for
baseline body weight (Table 1). There was no correlation
between MFAP5 mRNA expression and fasting plasma
glucose levels.
Interestingly, at baseline, the mRNA expression of MFAP5
correlated negatively with fasting serum adiponectin and
positively with leptin concentrations. Moreover, a positive
correlation was also found for fasting plasma interleukin
(IL)-1Ra and a negative one for fasting plasma IL-1b
concentrations, when adjusted for baseline body weight
(Table 1). MFAP5 mRNA expression correlated positively with
leptin gene expression (Table 1) at baseline (adjusted for
baseline body weight) and with adiponectin and IL-6
expression after the WR (Table 1). However, at the expres-
sion level, there was no correlation with cytokines like
transforming growth factor beta 1, tumour necrosis factor
alpha, IL-1b or IL-1Ra (Table 1).
Taken into account that MFAP5 is involved in the NOTCH
pathway,
9 we studied the correlation of MFAP5 mRNA
expression with NOTCH1 and NOTCH2 mRNA expressions.
MFAP5 mRNA expression did not correlate with the expres-
sions of these genes.
We also studied whether MFAP5 mRNA expression is
correlated with expressions of genes, which are involved in
modulation of AT formation. MFAP5 expression correlated
positively with peroxisome proliferator-activated receptor
gamma (PPARg), cyclin D2 (CCND2) and a disintegrin and
metalloproteinase domain 12 (ADAM12) mRNA expressions at
baseline (adjusted for baseline body weight), as well as after
the WR (Table 1), when adjusted for the corresponding body
weight.
The change in MFAP5 mRNA expression level correlated
significantly with the change IN body fat mass (r¼0.392,
P¼0.009). Furthermore, the change of MFAP5 expression
level correlated significantly with the changes of ADAM12,
adiponectin (ADIPOQ) and NOTCH2 expression levels
(r¼0.343, P¼0.026; r¼0.433, P¼0.004; r¼0.438, P¼0.006),
respectively, when adjusted for the change of body weight
and the WR and control groups were combined. When the
groups were analyzed separately, there was also a significant
correlation in the WR group between the change of MFAP5
mRNA expression and the change of ADIPOQ mRNA
expression. In the control group, there were no significant
correlations.
Discussion
MFAP5 is associated with microfibrils in elastin networks in a
number of tissues, and its function may be related to cell
signaling during microfibril assembly, elastogenesis and cell
survival.
5,10,11 It has been shown that MFAP5 promotes
angiogenesis and interacts with NOTCH1 by either activat-
ing or suppressing its activity, depending on the cell type
involved.
9,12 Furthermore, MFAP5 is increased in fibrotic
skin of humans and in mouse models with systemic
sclerosis.
13 Whether its function in AT is similar to previous
findings is not known.
ECM is composed of structural and multifunctional
molecules such as collagen, adhesive glycoproteins and
proteoglycans.
14,15 In AT, ECM maintains the structural
integrity of adipocytes, and has an important role in AT
formation.
15 Development of obesity induces changes in AT
(e.g., adipocyte hypertrophy, new adipocyte formation),
which are associated with remodeling of ECM proteins and
angiogenesis.
14,15,16 Genes related to ECM and cytoskeleton
have been shown to be upregulated by high-fat diet and
Figure 1 Fold changes of MFAP5 mRNA expression (y axis) using QPCR
(gray bars) and microarray analysis (black bars) in the weight reduction group
and control group. Po0.05 was considered statistically significant. MFAP5
gene expressed after the intervention divided by the intensity at baseline:
*P¼0.017, **P¼0.004 (comparisons were made within groups),
#P¼0.028
(comparison was made between groups).
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14,17 Not only weight
gain induces ECM remodeling but also weight loss modifies
the expression of ECM molecules.
15 The chronic proinflam-
matory state in obesity is suggested to be associated with
ECM remodeling and subsequent interstitial fibrosis. It has
also been shown that human preadipocytes secrete fibrotic
factors because of inflammatory stimulus.
18
Recent human and rodent studies have demonstrated
that collagen VI is highly expressed in obese state and
is associated with increased BMI, adipose fat mass and
inflammation. There is also evidence that a loss of collagen
VI in AT leads to improvements of metabolic profile.
19–21
Expression changes in microfibrillar proteins such as MFAP5,
is known to participate in collagen synthesis and accumu-
lation.
22 Lemaire et al.
23 have demonstrated that MFAP5
could enhance type I collagen matrix by stabilizing type I
procollagen. Furthermore, it has been shown that MAGP-1,
which is structurally related molecule to MFAP5, could
bind to type VI collagen. It could also be possible that
MFAP5 might bind to collagen VI or other ECM molecules
of AT, but only fibrillin 1 has been shown to interact with
MFAP5.
23
Our results showed that MFAP5 expression was correlated
with the change of body fat mass, fasting serum adiponectin
and leptin. Reduced adiponectin levels and increased leptin
levels are associated with obesity and insulin resistance.
24
Moreover, adiponectin and leptin are involved in obesity-
related angiogenesis and ECM remodeling.
16,24 Therefore,
the found correlation between the MFAP5 gene expression
and adiponectin and leptin might be related to angiogenesis
and ECM remodeling during development of obesity and
reduction of body fat mass along with WR.
In addition to MFAP5, also specific ADAM isoforms are
shown to be involved in NOTCH pathway. Moreover, ADAM12,
CCND2, NOTCH receptors and PPARg are known to be
involved in the development of AT, differentiation and
Table 1 Correlations of MFAP5 mRNA expression in subcutaneous adipose tissue with anthropometric, biochemical measures, and with selected genes expressed in
subcutaneous adipose tissue before and after the intervention in weight reduction and control groups; adjusted for body weight
Groups combined (n¼46) Weight reduction group (n¼28) Control group (n¼18)
0 week 34 weeks 34 weeks
r
a P-value r
a P-value r
a P-value
Anthropometric and biochemical measures
Body mass index (kgm
 2)
b 0.369
#### 0.014 0.06811 0.737 0.128 0.613
Body weight (kg)
b 0.043
### 0.785  0.2131 0.297  0.122
  0.641
Body fat mass (kg)
b 0.277
#### 0.069 0.05211 0.798 0.114 0.653
Waist circumference (cm) 0.282
### 0.071 0.4311 0.032  0.011
  0.968
SI ((mUl
 1)
 1 min
 1)  0.260
## 0.101  0.1621 0.439  0.429
  0.017
fS-adiponectin (mgml
 1)  0.378
### 0.014  0.36911 0.063  0.626
  0.009
fS-leptin (ngml
 1) 0.361
### 0.019 0.1551 0.459 0.153
  0.571
fS-insulin (pmoll
 1) 0.397
## 0.010 0.1651 0.429 0.352
  0.181
fP-glucose (mmoll
 1) 0.132
## 0.41  0.0931 0.66 0.358
  0.174
fS-TNFa (pgml
 1)  0.162
### 0.305  0.2961 0.151 0.028
  0.919
fP-IL1b (pgml
 1)  0.401
### 0.009  0.221 0.29 -0.207
  0.441
fP-IL1Ra (pgml
 1) 0.347
### 0.024 0.3251 0.113 0.469
  0.067
hsCRP (mgl
 1) -0.021
### 0.895 -0.1061 0.615 -0.076
  0.781
Gene expression in adipose tissue (AU)
Leptin 0.338
### 0.028 0.2591 0.211 0.357
  0.174
Adiponectin 0.033
### 0.838 0.4881 0.013 0.011
  0.968
PPAR-g 0.511
### 0.001 0.6211 0.001 0.195
  0.469
TNF-a 0.132
### 0.404 0.0181 0.932 0.39
  0.136
IL1-b 0.071
## 0.659 0.140* 0.524 0.09
  0.741
IL-1Ra 0.106
### 0.504 0.054* 0.807 0.386
  0.14
IL-6 0.007
### 0.966 0.4091 0.042  0.267
  0.317
TGF-b1 0.25
# 0.12 0.388* 0.067 0.089
  0.743
NOTCH1  0.277
# 0.083  0.191* 0.383  0.121
  0.656
NOTCH2 0.191
# 0.239 0.324* 0.131 0.37
  0.158
CCND2 0.523
### o0.001 0.4011 0.047 0.392
  0.133
ADAM22 0.248
### 0.114 0.261* 0.229 0.473
  0.064
ADAM12 0.584
### o0.001 0.5521 0.004 0.579
  0.019
Abbreviations: ADAM12, A disintegrin and metalloproteinase domain 12; ADAM22, A disintegrin and metalloproteinase domain 22; AU, arbitrary unit; CCND2,
cyclin D2; fP, fasting plasma; fS, fasting serum; hsCRP, high-sensitivity C reactive protein; IL-6, interleukin 6; IL-1Ra, interleukin 1 receptor antagonist; IL-1b,
interleukin 1 beta; NOTCH1, notch1 preproprotein; NOTCH2, notch2 preproprotein; PPARg, peroxisome proliferator-activated receptor gamma; SI, insulin
sensitivity index; TGF-b1, transforming growth factor beta 1; TNF-a, tumour necrosis factor alpha.
aAdjusted for body weight (kg).
bCorrelation analyses were carried
out using Pearson’s method, no adjustments;
#n¼41;
##n¼42;
###n¼43;
####n¼44; *n¼24; 1n¼26; 11n¼27;
 n¼17. Values are logarithmized, when
appropriate. Bold font: result statistically significant (Po0.05).
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25–27 Interestingly, our results showed a correla-
tion between MFAP5 mRNA expression and PPARg, CCND2
and ADAM12 mRNA expressions at baseline and after the
intervention, as well as with the changes of ADAM12,
ADIPOQ and NOTCH2 gene expressions. It is possible that
the effect of MFAP5 on angiogenesis or the role of MFAP5
gene in AT remodeling is mediated via factors related to
adipogenesis and differentiation. It could also be possible
that MFAP5 is a ‘structure’ gene and an ‘innocent bystander’
that will respond along with other ECM proteins to state of
obesity and adipokines secreted by AT. Further studies are
necessary to determine which mechanisms might be in-
volved in the regulation of MFAP5 expression in adipocytes.
In conclusion, MFAP5 is highly expressed in AT and is
correlated with markers of insulin resistance. It is possible
that MFAP5 is involved in ECM remodeling, which enables
AT enlargement in obesity. This process seems to be
reversible, at least partly, along with WR.
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